Carisma to develop allogeneic macrophage therapies Carisma Therapeutics has established a multiyear scientific collaboration with Dr. Bruce Blazar of the University of Minnesota to investigate and develop allogeneic macrophage therapies.Read More
PerkinElmer contributes to PROTACs research PerkinElmer is serving as a provider and co-developer of assays, instruments, and expertise for the ProxiDrugs Consortium, which is zeroing in on research for proximity drugs or proteolysis-targeting chimeras (PROTACs).Read More
CDISC, NORD partner to develop data standards for rare diseases The Clinical Data Interchange Standards Consortium (CDISC) and the National Organization for Rare Disorders (NORD) announced a partnership to develop global data standards for rare diseases. The data standards will be available at no cost on the CDISC website for researchers to leverage in studies.Read More
NIH grants Vaxess $2.9M to develop vaccine patch Vaxess Technologies announced it has received a $2.9 million grant from the National Institute of Allergy and Infectious Diseases, an agency of the U.S. National Institutes of Health (NIH), to evaluate and commercialize a method for delivering vaccines through a next-generation, sustained-release intradermal microneedle patch.Read More
Valneva begins phase III COVID-19 vaccine trial Valneva announced it has initiated a phase III trial to evaluate its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001. The company's Cov-Compare trial will pit VLA2001 against AstraZeneca's conditionally approved vaccine, Vaxzevria, in a comparative immunogenicity trial.Read More
Vertex, Obsidian partner on regulated gene editing therapies Vertex Pharmaceuticals and Obsidian Therapeutics have entered a research collaboration and licensing agreement focused on the discovery of novel therapies that regulate gene editing for the treatment of serious diseases.Read More